AtriCure Inc
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and li… Read more
AtriCure Inc (ATRC) - Net Assets
Latest net assets as of September 2025: $476.51 Million USD
Based on the latest financial reports, AtriCure Inc (ATRC) has net assets worth $476.51 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($635.44 Million) and total liabilities ($158.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $476.51 Million |
| % of Total Assets | 74.99% |
| Annual Growth Rate | 27.48% |
| 5-Year Change | 11.78% |
| 10-Year Change | 146.92% |
| Growth Volatility | 217.8 |
AtriCure Inc - Net Assets Trend (2001–2024)
This chart illustrates how AtriCure Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AtriCure Inc (2001–2024)
The table below shows the annual net assets of AtriCure Inc from 2001 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $460.97 Million | -1.12% |
| 2023-12-31 | $466.17 Million | +2.06% |
| 2022-12-31 | $456.75 Million | -5.58% |
| 2021-12-31 | $483.76 Million | +17.30% |
| 2020-12-31 | $412.39 Million | +66.73% |
| 2019-12-31 | $247.34 Million | -0.82% |
| 2018-12-31 | $249.38 Million | +54.74% |
| 2017-12-31 | $161.17 Million | -4.32% |
| 2016-12-31 | $168.44 Million | -9.77% |
| 2015-12-31 | $186.69 Million | +40.85% |
| 2014-12-31 | $132.54 Million | +82.55% |
| 2013-12-31 | $72.60 Million | +480.83% |
| 2012-12-31 | $12.50 Million | -19.95% |
| 2011-12-31 | $15.61 Million | -6.70% |
| 2010-12-31 | $16.74 Million | -2.07% |
| 2009-12-31 | $17.09 Million | -41.31% |
| 2008-12-31 | $29.12 Million | -19.64% |
| 2007-12-31 | $36.24 Million | +18.06% |
| 2006-12-31 | $30.69 Million | -28.92% |
| 2005-12-31 | $43.18 Million | +258.00% |
| 2004-12-31 | $-27.33 Million | -44.33% |
| 2003-12-31 | $-18.94 Million | -211.26% |
| 2002-12-31 | $17.02 Million | +883.25% |
| 2001-12-31 | $1.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AtriCure Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39828100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $49.00K | 0.01% |
| Other Comprehensive Income | $-1.03 Million | -0.22% |
| Other Components | $863.71 Million | 187.37% |
| Total Equity | $460.97 Million | 100.00% |
AtriCure Inc Competitors by Market Cap
The table below lists competitors of AtriCure Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Asker Healthcare Group AB
F:I88
|
$1.38 Billion |
|
Kontron AG
VI:KTN
|
$1.39 Billion |
|
Kangwon Land
KO:035250
|
$1.39 Billion |
|
Intercorp Financial Services Inc
NYSE:IFS
|
$1.39 Billion |
|
SPAREBK 1 NORD-NORGE NK18
F:93S
|
$1.38 Billion |
|
Beijing Zhong Ke San Huan High-Tech Co Ltd
SHE:000970
|
$1.38 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
$1.38 Billion |
|
Polaris Bay Group Co Ltd
SHG:600155
|
$1.38 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AtriCure Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 466,168,000 to 460,969,000, a change of -5,199,000 (-1.1%).
- Net loss of 44,698,000 reduced equity.
- Share repurchases of 6,951,000 reduced equity.
- Other comprehensive income decreased equity by 42,000.
- Other factors increased equity by 46,492,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-44.70 Million | -9.7% |
| Share Repurchases | $6.95 Million | -1.51% |
| Other Comprehensive Income | $-42.00K | -0.01% |
| Other Changes | $46.49 Million | +10.09% |
| Total Change | $- | -1.12% |
Book Value vs Market Value Analysis
This analysis compares AtriCure Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.94x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 29.43x to 2.94x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $0.98 | $28.85 | x |
| 2002-12-31 | $9.58 | $28.85 | x |
| 2003-12-31 | $-10.57 | $28.85 | x |
| 2004-12-31 | $-14.95 | $28.85 | x |
| 2005-12-31 | $7.17 | $28.85 | x |
| 2006-12-31 | $2.53 | $28.85 | x |
| 2007-12-31 | $2.71 | $28.85 | x |
| 2008-12-31 | $2.05 | $28.85 | x |
| 2009-12-31 | $1.17 | $28.85 | x |
| 2010-12-31 | $1.11 | $28.85 | x |
| 2011-12-31 | $1.00 | $28.85 | x |
| 2012-12-31 | $0.77 | $28.85 | x |
| 2013-12-31 | $3.55 | $28.85 | x |
| 2014-12-31 | $5.03 | $28.85 | x |
| 2015-12-31 | $6.65 | $28.85 | x |
| 2016-12-31 | $5.33 | $28.85 | x |
| 2017-12-31 | $4.98 | $28.85 | x |
| 2018-12-31 | $7.32 | $28.85 | x |
| 2019-12-31 | $6.58 | $28.85 | x |
| 2020-12-31 | $9.79 | $28.85 | x |
| 2021-12-31 | $10.51 | $28.85 | x |
| 2022-12-31 | $9.99 | $28.85 | x |
| 2023-12-31 | $10.07 | $28.85 | x |
| 2024-12-31 | $9.82 | $28.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AtriCure Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9.61%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 1.32x
- Recent ROE (-9.70%) is above the historical average (-31.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -207.74% | -17980.00% | 0.01x | 1.18x | $-3.77 Million |
| 2002 | -53.06% | -511.38% | 0.10x | 1.03x | $-10.73 Million |
| 2003 | 0.00% | -72.59% | 0.66x | 0.00x | $-5.21 Million |
| 2004 | 0.00% | -49.34% | 1.50x | 0.00x | $-6.72 Million |
| 2005 | -29.37% | -40.97% | 0.62x | 1.16x | $-17.00 Million |
| 2006 | -44.69% | -35.87% | 0.98x | 1.27x | $-16.79 Million |
| 2007 | -31.05% | -23.29% | 1.05x | 1.27x | $-14.88 Million |
| 2008 | -34.92% | -18.40% | 1.27x | 1.49x | $-13.08 Million |
| 2009 | -96.52% | -30.25% | 1.56x | 2.05x | $-18.20 Million |
| 2010 | -22.66% | -6.43% | 1.75x | 2.01x | $-5.47 Million |
| 2011 | -34.94% | -8.47% | 1.90x | 2.17x | $-7.02 Million |
| 2012 | -60.27% | -10.73% | 2.17x | 2.59x | $-8.78 Million |
| 2013 | -15.79% | -14.00% | 0.73x | 1.54x | $-18.72 Million |
| 2014 | -12.23% | -15.09% | 0.68x | 1.20x | $-29.46 Million |
| 2015 | -14.58% | -20.97% | 0.48x | 1.46x | $-45.88 Million |
| 2016 | -19.79% | -21.49% | 0.56x | 1.64x | $-50.18 Million |
| 2017 | -16.69% | -15.39% | 0.65x | 1.66x | $-43.01 Million |
| 2018 | -8.48% | -10.48% | 0.57x | 1.43x | $-46.08 Million |
| 2019 | -14.23% | -15.25% | 0.41x | 2.26x | $-59.93 Million |
| 2020 | -11.68% | -23.32% | 0.29x | 1.73x | $-89.39 Million |
| 2021 | 10.38% | 18.30% | 0.45x | 1.27x | $1.82 Million |
| 2022 | -10.17% | -14.06% | 0.56x | 1.28x | $-92.14 Million |
| 2023 | -6.53% | -7.62% | 0.65x | 1.32x | $-77.05 Million |
| 2024 | -9.70% | -9.61% | 0.76x | 1.32x | $-90.79 Million |
Industry Comparison
This section compares AtriCure Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $803,008,313
- Average return on equity (ROE) among peers: -163.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AtriCure Inc (ATRC) | $476.51 Million | -207.74% | 0.33x | $1.38 Billion |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $520.03 Million | 8.62% | 0.25x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $2.56 Billion | 36.42% | 1.05x | $36.83 Billion |
| Align Technology Inc (ALGN) | $161.15 Million | 22.17% | 0.38x | $11.50 Billion |
| AngioDynamics Inc (ANGO) | $372.19 Million | 2.67% | 0.10x | $344.14 Million |
| Ansell Limited (ANSLF) | $1.56 Billion | 10.20% | 0.61x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $7.93 Billion |
| Avinger Inc (AVGR) | $4.24 Million | -1323.46% | 11.63x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $18.90 Million | -243.53% | 0.62x | $156.14 Million |